Saturday, December 2, 2023
Clinical Advances in the Management of
Chronic hyperkalemia is a challenging clinical problem associated with increased mortality in patients with chronic kidney disease. The risk of hyperkalemia is also a limiting factor in usingrenin-angiotensin-aldosterone system (RAAS) inhibitors for the treatment of hypertension, chronic kidney disease, heart failure, and diabetes. This page aims to inform clinicians on the latest clinical trial updates and how to implement evolving standards of care that reflect the latest clinical evidence on RAAS inhibition and hyperkalemia management to improve patient outcomes.
Supported by an independent educational grant from
Relypsa, A Vifor Pharma Group Company
Overview of hyperkalemia and current evidence for novel potassium binders.
Download
Chair
Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois
Patrick A. Lehan Chair in
Cardiovascular Research
Professor of Medicine and Physiology
University of Mississippi
Jackson, Mississippi
Professor of Medicine
Miller School of Medicine
University of Miami
Miami, Florida
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clinical Trials Program
Division of Nephrology
University of Tennessee Health Science Center
Nephrology Section Chief
Memphis VA Medical Center
Memphis, Tennessee
Professor of Medicine
Wayne State University
Detroit, Michigan, United States
Clinical Professor of Medicine
Central Michigan University
Mt. Pleasant, Michigan, United States
Professor of Medicine
Director, Division of Neurology
University of Maryland
School of Medicine
Baltimore, Maryland
Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Anlynium; KBP; Merck; Relypsa
Received grants for clinical research from: Bayer; Novo Nordisk; Vascular Dynamics
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Abbott; Amgen; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CVRx; Janssen; LivaNova; Luitpold; Medtronic; Merck; Novartis; Relypsa; Vifor
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim/Lilly; Janssen; Novartis
Disclosure: Murray Epstein, MD, has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bayer Healthcare; Relypsa Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Bayer; Cara Therapeutics; Reata; Takeda; Tricida
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Relypsa
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Boehringer Ingelheim; Janssen; Lupin; Merck Sharp & Dohme; Relypsa; Vifor